Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 EV-to-EBITDA is -20.44 as of Aug. 09, 2026. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 401 Biotechnology companies, StemCyte International ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, StemCyte International's enterprise value is NT$2,041.4 Mil.
StemCyte International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-99.8 Mil. Therefore, StemCyte International's EV-to-EBITDA for today is -20.44.
The historical rank and industry rank for StemCyte International's EV-to-EBITDA or its related term are showing as below:
TPE:4178'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -107.25 Med: -30.46 Max: -14.06
Current: -20.44
During the past 4 years, the highest EV-to-EBITDA of StemCyte International was -14.06. The lowest was -107.25. And the median was -30.46.
TPE:4178's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.12
vs TPE:4178: -20.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
StemCyte International (TPE:4178) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
StemCyte International's PE Ratio (TTM) for today is calculated as:
StemCyte International's share price for today is NT$18.40.
StemCyte International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, StemCyte International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where StemCyte International's EV-to-EBITDA falls into.
StemCyte International's current Enterprise Value is NT$2,041.4 Mil.
StemCyte International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-99.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a EV-to-EBITDA of -20.44 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on StemCyte International. According to the industry distribution chart, StemCyte International ranks #999999 out of 401 companies in the Biotechnology industry.
Is StemCyte International's EV-to-EBITDA too high?
StemCyte International's current EV-to-EBITDA is -20.44. Based on the distribution chart, StemCyte International ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #999999 out of 401 companies for EV-to-EBITDA. This places StemCyte International in the lower half of its industry. The industry median EV-to-EBITDA is 13.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.12, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on StemCyte International. For the Biotechnology industry, the median EV-to-EBITDA is 13.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current EV-to-EBITDA is -20.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current EV-to-EBITDA of -20.44. The current EV-to-EBITDA is -20.44. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current EV-to-EBITDA is -20.44 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
